# Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

> **NCT03652441** · PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 14 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT03652441
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2023-08-10
- **Final completion:** 2025-01-25
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652441, "Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT03652441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*